Authors


Gilles Salles, MD, PhD

Latest:

Bispecific Antibodies Look Promising in Follicular Lymphoma

The use of bispecific antibodies has the potential to revolutionize the management of FL.


David M. Waterhouse, MD, MPH

Latest:

Expert Highlights Immunotherapy Advances in Lung Cancer Treatment Landscape

David M. Waterhouse, MD, MPH, shares advice with community oncologists treating patients with lung cancer.


Alan Tan, MD

Latest:

Tan Explores the Potential of ctDNA in Renal Cell Carcinoma

Alan Tan, MD, discusses areas of interest in the research and development of circulating tumor DNA in renal cell carcinoma.


Hagop M. Kantarjian

Latest:

Kantarjian on Solutions for Oncology Drug Shortages

According to Hagop M. Kantarjian, MD, there are options for limited oncology drug shortages that require multi-sector involvement.


Hayley Virgil

Latest:

Olaparib Plus Abiraterone/Prednisone Improves Survival in mCRPC

A promising new treatment combination of frontline olaparib plus abiraterone/prednisone has emerged for advanced prostate cancer with specific genetic alterations.


Suresh S. Ramalingam, MD

Latest:

FLAURA Trial Demonstrates Efficacy in EGFR-Positive Lung Cancer

Suresh S. Ramalingam, MD, discusses the phase III FLAURA trial.


Katherine E. Poruk, MD

Latest:

Melanoma Monday: A Review of the MSLT-II Trial and Completion Lymph Node Dissection

Katherine E. Poruk, MD, reviews the use of complete axillary lymph node dissection and the Multicenter Selective Lymphadenectomy Trial II for Melanoma Monday.


Andrew Srisuwananukorn, MD

Latest:

Utilizing Interpretable AI to Distinguish prePMF From ET

Andrew Srisuwananukorn, MD, discusses the main findings from research of an artificial intelligence-powered machine learning algorithm which evaluated digital whole-slide images of diagnostic bone marrow biopsies and accurately differentiated prefibrotic primary myelofibrosis from essential thrombocythemia.


Andrei Gafita, MD

Latest:

Investigating Prognostic Markers for OS With LuPSMA Treatment in mCRPC

Andrei Gafita, MD, discusses the overall survival in patients with metastatic castration-resistant prostate cancer who received 177Lutetium-prostate-specific membrane antigen radionuclide treatment.


Nasir Chaudry, MD

Latest:

Choosing the Optimal Treatment for Patients With Prostate Cancer

Nasir Chaudry, MD, discusses treatment decisions for patients with prostate cancer and the importance of individualized treatment based on the specific case and patient preferences.


Ibrahim N. Muhsen, MD

Latest:

Efficacy and Safety: Brexu-cel's Impact on CNS Response in B-ALL

Ibrahim N. Muhsen, MD, discusses the findings and key takeaways from his presentation given at the 2024 Tandem Meeting.


Darlene Dobkowski, MA

Latest:

Adding Darolutamide to ADT May Reduce Hospitalizations But Longer Stays in mHSPC

Patients with metastatic hormone-sensitive prostate cancer treated with darolutamide plus androgen deprivation therapy and docetaxel had lower rates of hospitalizations but marginally longer lengths of stay compared with those treated with placebo, androgen deprivation therapy, and docetaxel.


Marin F. Xavier, MD

Latest:

Next Steps Using Anti-CD19 Therapies in DLBCL

The future of combined treatment approaches with anti-CD19 therapies for diffuse large B-cell lymphoma.


Andrew G. Gianoukakis, MD

Latest:

Multikinase Inhibitor Options Flourish for Patients With RET-Mutant Medullary Thyroid Cancer

During a Targeted Oncology Case-Based Peer Perspectives event, Andrew G. Gianoukakis, MD, FACE, discussed the use of multikinase inhibitors for RET-mutated medullary thyroid cancer.


Melissa M. Hardesty, MD

Latest:

Further Research Needed to Improve Outcomes in Advanced Ovarian Cancer

Melissa M. Hardesty discusses the key takeaways of the phase 2 OVARIO study of a PARP inhibitor plus a VEGF inhibitor in women with advanced ovarian cancer as well as research still needs to examine in this space.


Rupesh Kotecha, MD

Latest:

Key Takeaways Regarding Use of 45 Gy Novel Radiotherapy in CNS Cancers

Rupesh Kotecha, MD, discusses the key findings from an analysis centered around the use of pulse reduced dose rate intensity-modulated radiotherapy in patients with central nervous system malignancies.


David I. Quinn, MD, PhD, MBBS

Latest:

Roundtable Discussion: Addressing Management of Patients with Metastatic CRPC Following Frontline Treatments

During a Targeted Oncology Case-Based Roundtable event, David I. Quinn, MD, PhD, MBBS leads a discussion on treatment for metastatic castration-resistant prostate cancer following frontline treatment.


Parvez Mantry, MD

Latest:

Future Treatment Approaches for HCC

Closing out their discussion on the management of hepatocellular carcinoma, panelists discuss future novel therapies that may impact the treatment landscape.


Srikanth Nagalla, MD, MS

Latest:

Hematology Workforce Shortage Poses Challenges for Cancer Care

Srikanth Nagalla, MD, MS, describes initiatives to improve the talent pipeline for hematology staff at all levels.


Chelsea Peterson, DO

Latest:

Peterson on Second-Line Ruxolitinib in Acute GVHD

Peterson discusses the investigation of ruxolitinib in the second line for patients with acute graft-vs-host disease following allogeneic hematopoietic stem cell transplant.


Ashley Hay, BSN, RN

Latest:

Immune Checkpoint to Watch: ICOS

Developing modern strategies to predict and accurately monitor treatment response remains an important piece of the clinical management puzzle.



Kushal Naha, MD

Latest:

Keeping Track of FGFR Inhibitor AEs Leads to Optimal Outcomes

This article explorex some of the more frequently encountered toxicities of FGFR inhibitors and their optimal management.


Usama Gergis, MD

Latest:

Gergis Explains the Differences Between Acute and Chronic GVHD

Usama Gergis, MD, MBA, reviewed that difference in acute and chronic graft-versus-host disease and the treatment available for each


Susanne G. Warner, MD

Latest:

Tailoring Treatments to Better Outcomes in Liver Cancer

In season 4, episode 16 of Targeted Talks, Susanne G. Warner, MD,discusses the importance of tailoring treatments for patients with liver cancer, taking into account the staging of the cancer.


Charles L. Sawyers, MD

Latest:

The Importance of IMspire150 Data Is Questioned in Melanoma Treatment Landscape

Charles L. Sawyers, MD, discusses the value of atezolizumab, cobimetinib, and vemurafenib in the melanoma treatment landscape.


Amer Zeidan, MBBS, MHS

Latest:

Imetelstat May Help Fill Unmet Needs in MDS Treatment

Amer Zeidan, MBBS, discusses the unmet needs that exist for myelodysplastic syndromes and how imetelstat may help fill these needs.


Elizabeth Wulff-Burchfield, MD

Latest:

Clinical Pearls for Community Oncologists Treating RCC

Expert genitourinary oncologists close their discussion with advice to community oncologists treating renal cell carcinoma.


Michael Scordo, MD

Latest:

Scordo on Model-Based ATG Dosing in Allo-HCT

Michael Scordo, MD, discusses the implications of a new approach to dosing antithymocyte globulin in patients undergoing an allogeneic hematopoietic stem cell transplant.


Daniel Landau, MD

Latest:

PARP Inhibition in Metastatic CRPC: The PROfound and TRITON2 Studies

Expert perspectives on the PROfound and TRITON2 studies of olaparib and rucaparib, respectively, in metastatic castration-resistant prostate cancer.